v3.25.1
Balance Sheet Components - Intangible Assets, Net (Details) - USD ($)
$ in Thousands
3 Months Ended
Mar. 31, 2025
Mar. 31, 2024
Dec. 31, 2024
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]      
Finite-lived assets, net of accumulated amortization of $2,719 and $639, as of December 31, 2024 and 2023, respectively $ 24,120   $ 24,787
Accumulated amortization 3,386   2,719
Indefinite-lived assets - in-process research and development 28,859   28,859
Total Intangible assets, net 52,979   $ 53,646
Amortization expense, Finite-lived intangible assets $ 700 $ 900  
Impairment of out-license asset and remeasurement of CVR liability, net   6,772  
Surface Acquisition      
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]      
Fair value of the contingent consideration   3,800  
Contingent consideration, current   0  
Novartis Institutes | Surface Acquisition      
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]      
Impairment of out-license asset and remeasurement of CVR liability, net   $ 6,800  
Impairment, Intangible Asset, Finite-Lived, Statement of Income or Comprehensive Income [Extensible Enumeration]   Selling, General and Administrative Expense  
Impairment charge   $ 10,600